GLP-1 receptor agonists continue to demonstrate benefits beyond glucose control and weight management. A large real-world study from UCLA Health suggests that these medications may also reduce the risk of serious fragility fractures in older adults with type 2 diabetes. Fragility fractures commonly affecting the hip, femur, and spine occur after minor falls and are often associated with weakened bones, posing a major cause of disability and mortality in older individuals.

      The study, published in JAMA Network Open, analyzed electronic health records from nearly 134,000 U.S. adults aged 50–90 years with type 2 diabetes. Researchers compared new users of GLP-1 receptor agonists with individuals initiating DPP-4 inhibitors and found that GLP-1 therapy was associated with a 21% lower risk of fragility fractures over a three-year follow-up period. The greatest reduction was observed in fractures involving the hip, femur, and spine. Interestingly, this protective association was seen only among participants with type 2 diabetes and was not observed in a matched cohort without diabetes.

      Although concerns have been raised that rapid weight loss with GLP-1 therapy could compromise bone health, these findings provide reassuring evidence that GLP-1 receptor agonists do not appear to increase fracture risk and may even offer skeletal protection in people with type 2 diabetes. However, as this was a retrospective observational study, the authors emphasize that the findings demonstrate an association rather than causation. Further prospective clinical trials are needed to confirm the mechanisms involved and determine the long-term effects of GLP-1 therapy on bone health.

Read More